Skip to content

Abnormal Enchondral Ossification C4025628

Published: July 22, 2026Updated: August 26, 2026

Impaired bone formation from cartilage during development. Often seen in skeletal disorders and may affect bone growth and structure.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 26, 2026Editorial policy

Key facts at a glance

ICD-10
Q79.9
ICD-11
LA00.0
Body system
musculoskeletal
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Restrictive Lung Disease

Reduced lung capacity due to chest wall deformities affecting respiratory function.

Seek immediate care for shortness of breath, chest pain, or difficulty breathing.

!

Spinal Cord Compression

Compression of spinal nerves or cord due to severe vertebral deformities, causing numbness or weakness.

Seek immediate care for sudden weakness, numbness, or loss of bladder/bowel control.

Skeletal Deformity

(musculoskeletal)

Abnormal curvature or malformation of bones, commonly affecting the limbs or spine due to improper bone development.

Frequency: 80-90% of patients

Short Stature

(constitutional)

Reduced height compared to peers due to impaired growth of long bones during development.

Frequency: 75-85% of patients

Joint Pain

(musculoskeletal)

Persistent pain in joints, particularly weight-bearing joints like knees and hips, due to abnormal cartilage development.

Frequency: 60-70% of patients

Limited Joint Mobility

(musculoskeletal)

Reduced range of motion in joints due to structural abnormalities and early joint degeneration.

Frequency: 50-60% of patients

Bone Pain

(musculoskeletal)

Deep bone pain, often worse at night or with weight-bearing activities, caused by abnormal bone structure.

Frequency: 50-65% of patients

Premature Osteoarthritis

(musculoskeletal)

Early-onset degenerative joint disease resulting from abnormal joint structure and cartilage integrity.

Frequency: 40-55% of patients

Increased Fracture Risk

(musculoskeletal)

Bones are more susceptible to fractures due to structural weakness from abnormal ossification.

Frequency: 35-45% of patients

Scoliosis

(musculoskeletal)

Lateral curvature of the spine that may develop due to asymmetric bone growth and vertebral abnormalities.

Frequency: 15-25% of patients

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Growth and Skeletal Development Monitoring

Regular assessment of bone growth, skeletal maturity, and height velocity through radiographs and physical examination. Monitoring allows for early identification of abnormalities and intervention timing.

monitoring
2

Lifestyle modification and dietary intervention

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
3

Nutritional Support and Supplementation

Calcium, vitamin D, and phosphate supplementation along with balanced nutrition to support proper bone formation. Adequate micronutrient intake is essential for normal enchondral ossification processes.

dietary

Additional treatment options

Corrective Orthopedic Surgery

Surgical intervention to correct skeletal deformities, limb length discrepancies, or structural abnormalities resulting from abnormal enchondral ossification. Procedures may include osteotomies, lengthening, or fusion.

surgical

Mobility and Strength Rehabilitation

Targeted physical therapy to maintain joint mobility, prevent contractures, and build supporting muscle strength. Therapeutic exercise supports bone loading necessary for healthy skeletal development.

physical_therapy

Pharmacological Management of Underlying Conditions

Treatment of primary conditions affecting bone metabolism such as vitamin D deficiency, hypothyroidism, or genetic disorders impacting ossification. Disease-specific medications address root causes.

medication

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Abnormal Enchondral Ossification C4025628?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

American College of Medical Genetics and Genomics. Clinical practice guideline: skeletal dysplasias. Genetics in Medicine. 2020.

guideline2020View source →
2

Warman ML, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2010 revision. American Journal of Medical Genetics Part A. 2011.

review2011View source →
3

Klag KA, Horton WA. Advances in treatment of achondroplasia and osteoarthritis. Human Molecular Genetics. 2016.

review2016View source →
4

Savarirayan R, Irving M, Maeda Y, et al. Effect of vosoritide on height in achondroplasia: a randomized, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2020.

clinical_trial2020View source →
5

Wallace SE, Krakow D. Achondroplasia: manifestation and treatment. Current Osteoporosis Reports. 2019.

meta_analysis2019View source →
6

International Skeletal Dysplasia Society. Nosology and classification of genetic skeletal disorders 2019 revision. American Journal of Medical Genetics Part A. 2019.

position_statement2019View source →
7

Ornitz DM, Legey-Meurani C. Regulation of skeletal growth and osteogenesis by fibroblast growth factors. Nature Reviews Endocrinology. 2012.

review2012View source →
8

Horton WA, Lunstrum GP. Fibroblast growth factor receptor 3 mutations in achondroplasia and related disorders. In: Rimoin DL, Pyeritz RE, Korf B, eds. Emery and Rimoin's Principles and Practice of Medical Genetics. 6th ed. Elsevier; 2013.

textbook2013
9

Ho H, Goto K, Sawada Y, et al. Long-term safety and efficacy of vosoritide in children with achondroplasia: 2-year results from a phase 3 trial. The Lancet Diabetes & Endocrinology. 2022.

clinical_trial2022View source →
10

Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet Journal of Rare Diseases. 2019.

consensus2019View source →

Medication Comparisons

Compare medications used to treat Abnormal Enchondral Ossification C4025628. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 26, 2026. · Read our editorial policy